Clinical trial · Interventional
A Prospective Trial of COXEN Chemotherapy Prediction
A Prospective Trial of COXEN Chemotherapy Prediction in Persistent and Recurrent Ovarian, Fallopian Tube, and Peritoneal Carcinomas
NCT01228942CI-TRIAL-00014791withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of funding/resources
Summary
Brief summary (as posted)
The purpose of this study is to determine if the COXEN algorithm, using the diagnostic device Affymetrix GeneChip, is able to predict which chemotherapies will be best for treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Neoplasms | Fallopian Tube Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| COXEN analysis for chemotherapy prediction | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Platinum Sensitive
- description
- Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet
- interventionNames
- Device: COXEN analysis for chemotherapy prediction
- type
- OTHER
- label
- Platinum resistent
- description
- single agent based on Coxen prediction model
- interventionNames
- Device: COXEN analysis for chemotherapy prediction
Primary outcomes (1)
- measure
- overall response rate
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria: * age greater than 18 * diagnosis of recurrent, persistent, refractory ovarian, fallopian or primary peritoneal cancer * tumor tissue, ascites or pleural fluid available for biopsy * life expectancy greater than 6 months Exclusion Criteria: * patients with borderline or low malignant histologies * patients with a history of other malignancies within last 5 years
References
Publications (0)
Data not yet available
No reference posted for this study.